-
1
-
-
59149085501
-
The global burden of hepatitis C
-
Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl 1):74-81.
-
(2009)
Liver Int
, vol.29
, Issue.SUPPL. 1
, pp. 74-81
-
-
Lavanchy, D.1
-
3
-
-
65449136656
-
American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: An update
-
Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Seeff, L.B.1
-
4
-
-
78650803266
-
HCV RESPOND-2 final results: High sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus pegintron/ribavirin
-
Bacon BR, Bruno S, Manns MP, Sulkowski MS. HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus pegintron/ribavirin. Hepatology 2010;52:430A.
-
(2010)
Hepatology
, vol.52
-
-
Bacon, B.R.1
Bruno, S.2
Manns, M.P.3
Sulkowski, M.S.4
-
5
-
-
78650820415
-
Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: Final results of phase 3 ADVANCE study
-
Jacobson IM. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. Hepatology 2010;52(427A).
-
(2010)
Hepatology
, vol.52
, Issue.427
-
-
Jacobson, I.M.1
-
6
-
-
78650806148
-
Boceprevir (BOC) combined with peginterferon alfa-2b/ ribavirin (P/R) for treatment-naive patients with hepatitis C (HCV) genotype 1: SPRINT-2 final results
-
Poordad F. Boceprevir (BOC) combined with peginterferon alfa-2b/ ribavirin (P/R) for treatment-naive patients with hepatitis C (HCV) genotype 1: SPRINT-2 final results. Hepatology 2010;52(402A).
-
(2010)
Hepatology
, vol.52
, Issue.402
-
-
Poordad, F.1
-
7
-
-
78751626981
-
Telaprevir in combination with peginterferon alfa2b and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: Final results of phase 3 ILLUMINATE study
-
Sherman KE. Telaprevir in combination with peginterferon alfa2b and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. Hepatology 2010;52(401A).
-
(2010)
Hepatology
, vol.52
, Issue.401
-
-
Sherman, K.E.1
-
8
-
-
79960453276
-
Management of hepatitis C virus infection
-
EASL Clinical Practice Guidelines
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64.
-
(2011)
J Hepatol
, vol.55
, pp. 245-264
-
-
-
9
-
-
23944506014
-
Global epidemiology of hepatitis C virus infection
-
DOI 10.1016/S1473-3099(05)70216-4, PII S1473309905702164
-
Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67. (Pubitemid 41196755)
-
(2005)
Lancet Infectious Diseases
, vol.5
, Issue.9
, pp. 558-567
-
-
Shepard, C.W.1
Finelli, L.2
Alter, M.J.3
-
10
-
-
36549067746
-
The changing epidemiology of hepatitis C virus infection in Europe
-
DOI 10.1016/j.jhep.2007.07.033, PII S0168827807005739
-
Esteban JL, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148-62. (Pubitemid 350191999)
-
(2008)
Journal of Hepatology
, vol.48
, Issue.1
, pp. 148-162
-
-
Esteban, J.I.1
Sauleda, S.2
Quer, J.3
-
11
-
-
0035056914
-
Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus
-
European Paediatric Hepatitis C Virus Network
-
European Paediatric Hepatitis C Virus Network. Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network. BJOG 2001;108:371-7.
-
(2001)
European Paediatric Hepatitis C Virus Network. BJOG
, vol.108
, pp. 371-377
-
-
-
13
-
-
0019948091
-
Sporadic non-A, non-B hepatitis: Frequency and epidemiology in an urban U.S. population
-
Alter MJ, Gerety RJ, Smallwood LA, Sampliner RE, Tabor E, Deinhardt F et al. Sporadic non-A, non-B hepatitis: frequency and epidemiology in an urban U.S. population. J Infect Dis 1982;145:886-93. (Pubitemid 12088968)
-
(1982)
Journal of Infectious Diseases
, vol.145
, Issue.6
, pp. 886-893
-
-
Alter, M.J.1
Gerety, R.J.2
Smallwood, L.A.3
-
14
-
-
25844523297
-
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes
-
DOI 10.1002/hep.20819
-
Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005;42:962-73. (Pubitemid 41401136)
-
(2005)
Hepatology
, vol.42
, Issue.4
, pp. 962-973
-
-
Simmonds, P.1
Bukh, J.2
Combet, C.3
Deleage, G.4
Enomoto, N.5
Feinstone, S.6
Halfon, P.7
Inchauspe, G.8
Kuiken, C.9
Maertens, G.10
Mizokami, M.11
Murphy, D.G.12
Okamoto, H.13
Pawlotsky, J.-M.14
Penin, F.15
Sablon, E.16
Shin-I, T.17
Stuyver, L.J.18
Thiel, H.-J.19
Viazov, S.20
Weiner, A.J.21
Widell, A.22
more..
-
15
-
-
78751621217
-
Evolving epidemiology of hepatitis C virus
-
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011:17:107-15.
-
(2011)
Clin Microbiol Infect
, vol.17
, pp. 107-115
-
-
Lavanchy, D.1
-
16
-
-
77950624760
-
The neglected hepatitis C virus genotypes 4, 5 and 6: An international consensus report
-
Antaki N, Craxi A, Kamal S, Moucari R, Van der Merwe S, Haffar S et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-55.
-
(2010)
Liver Int
, vol.30
, pp. 342-355
-
-
Antaki, N.1
Craxi, A.2
Kamal, S.3
Moucari, R.4
Van Der Merwe, S.5
Haffar, S.6
-
17
-
-
77958029477
-
Practice guidelines for the treatment of hepatitis C
-
recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting
-
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis 2010;42:81-91.
-
(2010)
Dig Liver Dis
, vol.42
, pp. 81-91
-
-
-
18
-
-
48749124393
-
Treatment of chronic hepatitis C virus infection - Dutch national guidelines
-
de Bruijne J, Buster EH, Gelderblom HC, Brouwer JT, de Knegt RJ, van Erpecum KJ et al. Treatment of chronic hepatitis C virus infection - Dutch national guidelines. Neth J Med 2008;66:311-22.
-
(2008)
Neth J Med
, vol.66
, pp. 311-322
-
-
De Bruijne, J.1
Buster, E.H.2
Gelderblom, H.C.3
Brouwer, J.T.4
De Knegt, R.J.5
Van Erpecum, K.J.6
-
19
-
-
34247216563
-
Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection
-
Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party
-
Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party, McCaughan GW, Omata M, Amarapurkar D, Bowden S, Chow WC et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-33.
-
(2007)
J Gastroenterol Hepatol
, vol.22
, pp. 615-633
-
-
McCaughan, G.W.1
Omata, M.2
Amarapurkar, D.3
Bowden, S.4
Chow, W.C.5
-
20
-
-
72249094116
-
Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection
-
Ascione A, De Luca M, Tartaglione MT, Lampasi F, Di Costanzo GG, Lanza AG et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterology 2010; 138:116-22.
-
(2010)
Gastroenterology
, vol.138
, pp. 116-122
-
-
Ascione, A.1
De Luca, M.2
Tartaglione, M.T.3
Lampasi, F.4
Di Costanzo, G.G.5
Lanza, A.G.6
-
21
-
-
68249154875
-
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
-
McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
-
(2009)
N Engl J Med
, vol.361
, pp. 580-593
-
-
McHutchison, J.G.1
Lawitz, E.J.2
Shiffman, M.L.3
Muir, A.J.4
Galler, G.W.5
McCone, J.6
-
22
-
-
72249083270
-
Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
-
Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology 2010;138:108-15.
-
(2010)
Gastroenterology
, vol.138
, pp. 108-115
-
-
Rumi, M.G.1
Aghemo, A.2
Prati, G.M.3
D'Ambrosio, R.4
Donato, M.F.5
Soffredini, R.6
-
23
-
-
0033919083
-
Adverse effects and other safety aspects of the hepatitis C antivirals
-
DOI 10.1046/j.1440-1746.2000.02114.x
-
Chutaputti A. Adverse effects and other safety aspects of the hepatitis C antivirals. J Gastroenterol Hepatol 2000;15(Suppl):E156-63. (Pubitemid 30435754)
-
(2000)
Journal of Gastroenterology and Hepatology
, vol.15
, Issue.SUPPL. MAY
-
-
Chutaputti, A.1
-
24
-
-
0036830507
-
Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C
-
DOI 10.1053/jhep.2002.36502
-
Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273-9. (Pubitemid 35253446)
-
(2002)
Hepatology
, vol.36
, Issue.5
, pp. 1273-1279
-
-
Soza, A.1
Everhart, J.E.2
Ghany, M.G.3
Doo, E.4
Heller, T.5
Promrat, K.6
Park, Y.7
Liang, T.J.8
Hoofnagle, J.H.9
-
25
-
-
77949320438
-
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: A review of the literature
-
Slavenburg S, Heijdra YF, Drenth JP. Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci 2010;55:579-85.
-
(2010)
Dig Dis Sci
, vol.55
, pp. 579-585
-
-
Slavenburg, S.1
Heijdra, Y.F.2
Drenth, J.P.3
-
26
-
-
1842463813
-
Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection
-
DOI 10.1111/j.1365-2893.2004.00490.x
-
Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-50. (Pubitemid 38658449)
-
(2004)
Journal of Viral Hepatitis
, vol.11
, Issue.3
, pp. 243-250
-
-
Sulkowski, M.S.1
Wasserman, R.2
Brooks, L.3
Ball, L.4
Gish, R.5
-
27
-
-
75649147072
-
Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag
-
Danish FA, Koul SS, Subhani FR, Rabbani AE, Yasmin S. Considerations in the management of hepatitis C virus-related thrombocytopenia with eltrombopag. Saudi J Gastroenterol 2010;16:51-6.
-
(2010)
Saudi J Gastroenterol
, vol.16
, pp. 51-56
-
-
Danish, F.A.1
Koul, S.S.2
Subhani, F.R.3
Rabbani, A.E.4
Yasmin, S.5
-
28
-
-
81355148539
-
Randomised clinical trial: Escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C
-
de Knegt RJ, Bezemer G, Van Gool AR, Drenth JP, Hansen BE, Droogleever Fortuyn HA et al. Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C. Aliment Pharmacol Ther 2011;34:1306-17.
-
(2011)
Aliment Pharmacol Ther
, vol.34
, pp. 1306-1317
-
-
De Knegt, R.J.1
Bezemer, G.2
Van Gool, A.R.3
Drenth, J.P.4
Hansen, B.E.5
Droogleever Fortuyn, H.A.6
-
29
-
-
0037179698
-
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
-
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
-
(2002)
N Engl J Med
, vol.347
, pp. 975-982
-
-
Fried, M.W.1
Shiffman, M.L.2
Reddy, K.R.3
Smith, C.4
Marinos, G.5
Gonçales Jr., F.L.6
-
30
-
-
1542378867
-
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose
-
Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
-
(2004)
Ann Intern Med
, vol.140
, pp. 346-355
-
-
Hadziyannis, S.J.1
Sette Jr., H.2
Morgan, T.R.3
Balan, V.4
Diago, M.5
Marcellin, P.6
-
31
-
-
0035934568
-
Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
-
DOI 10.1016/S0140-6736(01)06102-5
-
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
-
(2001)
Lancet
, vol.358
, Issue.9286
, pp. 958-965
-
-
Manns, M.P.1
McHutchison, J.G.2
Gordon, S.C.3
Rustgi, V.K.4
Shiffman, M.5
Reindollar, R.6
Goodman, Z.D.7
Koury, K.8
Ling, M.-H.9
Albrecht, J.K.10
-
32
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007;147:677-84. (Pubitemid 351664462)
-
(2007)
Annals of Internal Medicine
, vol.147
, Issue.10
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
Reichen, J.4
Hofmann, W.P.5
Zeuzem, S.6
Manns, M.P.7
Hansen, B.E.8
Schalm, S.W.9
Janssen, H.L.A.10
-
33
-
-
80052024078
-
Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future
-
Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. Hepatology 2011;54:789-800.
-
(2011)
Hepatology
, vol.54
, pp. 789-800
-
-
Di Martino, V.1
Richou, C.2
Cervoni, J.P.3
Sanchez-Tapias, J.M.4
Jensen, D.M.5
Mangia, A.6
-
34
-
-
79961234860
-
Treatment extension benefits HCV genotype 1 patients without rapid virological response: A systematic review
-
Gevers TJ, Slavenburg S, van Oijen MG, Drenth JP. Treatment extension benefits HCV genotype 1 patients without rapid virological response: a systematic review. Neth J Med 2011;69:216-21.
-
(2011)
Neth J Med
, vol.69
, pp. 216-221
-
-
Gevers, T.J.1
Slavenburg, S.2
Van Oijen, M.G.3
Drenth, J.P.4
-
35
-
-
62149105964
-
A study of best positive predictors for sustained virologie response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients
-
Idrees M, Riazuddin S. A study of best positive predictors for sustained virologie response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5.
-
(2009)
BMC Gastroenterol
, vol.9
, pp. 5
-
-
Idrees, M.1
Riazuddin, S.2
-
36
-
-
34547428001
-
Predictors of response of U.S. veterans to treatment for the hepatitis C virus
-
DOI 10.1002/hep.21662
-
Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 2007;46:37-47. (Pubitemid 47171919)
-
(2007)
Hepatology
, vol.46
, Issue.1
, pp. 37-47
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
Mole, L.A.4
-
37
-
-
33746535101
-
Peginterferon and ribavirin treatment in african american and caucasian american patients with hepatitis c genotype 1
-
DOI 10.1053/j.gastro.2006.06.008, PII S0016508506012376
-
Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006;131:470-7. (Pubitemid 44142464)
-
(2006)
Gastroenterology
, vol.131
, Issue.2
, pp. 470-477
-
-
Conjeevaram, H.S.1
Fried, M.W.2
Jeffers, L.J.3
Terrault, N.A.4
Wiley-Lucas, T.E.5
Afdhal, N.6
Brown, R.S.7
Belle, S.H.8
Hoofnagle, J.H.9
Kleiner, D.E.10
Howell, C.D.11
-
38
-
-
33846463006
-
Race, insulin resistance and hepatic steatosis in chronic hepatitis C
-
DOI 10.1002/hep.21455
-
Conjeevaram HS, Kleiner DE, Everhart JE, Hoofnagle JH, Zacks S, Afdhal NH et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7. (Pubitemid 46144367)
-
(2007)
Hepatology
, vol.45
, Issue.1
, pp. 80-87
-
-
Conjeevaram, H.S.1
Kleiner, D.E.2
Everhart, J.E.3
Hoofnagle, J.H.4
Zacks, S.5
Afdhal, N.H.6
Wahed, A.S.7
-
39
-
-
53049096125
-
Predictors of SVR in naive HCV G1 patients in real life practice: The PROBE
-
Suppl 2
-
Craxi A et al. Predictors of SVR in naive HCV G1 patients in real life practice: the PROBE. J Hepatol 2008;48(Suppl 2):S291.
-
(2008)
J Hepatol
, vol.48
-
-
Craxi, A.1
-
40
-
-
10744227418
-
The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients
-
DOI 10.1016/j.jhep.2003.11.004
-
Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallée M et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40:484-90. (Pubitemid 38230851)
-
(2004)
Journal of Hepatology
, vol.40
, Issue.3
, pp. 484-490
-
-
Patton, H.M.1
Patel, K.2
Behling, C.3
Bylund, D.4
Blatt, L.M.5
Vallee, M.6
Heaton, S.7
Conrad, A.8
Pockros, P.J.9
McHutchison, J.G.10
-
41
-
-
11144358311
-
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
-
discussion 947
-
Shiffman ML, Di Bisceglie AM, Lindsay KL, Morishima C, Wright EC, Everson GT et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 2004;126:1015-23; discussion 947.
-
(2004)
Gastroenterology
, vol.126
, pp. 1015-1023
-
-
Shiffman, M.L.1
Di Bisceglie, A.M.2
Lindsay, K.L.3
Morishima, C.4
Wright, E.C.5
Everson, G.T.6
-
42
-
-
2442683905
-
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3
-
DOI 10.1016/S0168-8278(04)00060-1, PII S0168827804000601
-
Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanchez-Tapias J et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9. (Pubitemid 38670134)
-
(2004)
Journal of Hepatology
, vol.40
, Issue.6
, pp. 993-999
-
-
Zeuzem, S.1
Hultcrantz, R.2
Bourliere, M.3
Goeser, T.4
Marcellin, P.5
Sanchez-Tapias, J.6
Sarrazin, C.7
Harvey, J.8
Brass, C.9
Albrecht, J.10
-
43
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance
-
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009;461:399-401.
-
(2009)
Nature
, vol.461
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
Simon, J.S.4
Shianna, K.V.5
Urban, T.J.6
-
44
-
-
70349548852
-
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
-
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
-
(2009)
Nat Genet
, vol.41
, pp. 1100-1104
-
-
Suppiah, V.1
Moldovan, M.2
Ahlenstiel, G.3
Berg, T.4
Weltman, M.5
Abate, M.L.6
-
45
-
-
70349533037
-
Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
-
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
-
(2009)
Nat Genet
, vol.41
, pp. 1105-1109
-
-
Tanaka, Y.1
Nishida, N.2
Sugiyama, M.3
Kurosaki, M.4
Matsuura, K.5
Sakamoto, N.6
-
46
-
-
11144358403
-
Epoetin alfa maintains ribavirin dose in hcv-infected patients: A prospective, double-blind, randomized controlled study
-
DOI 10.1053/j.gastro.2004.01.027
-
Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS et al. Epoetin alfa maintains ribavirin dose in HCVinfected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004;126:1302-11. (Pubitemid 38552795)
-
(2004)
Gastroenterology
, vol.126
, Issue.5
, pp. 1302-1311
-
-
Afdhal, N.H.1
Dieterich, D.T.2
Pockros, P.J.3
Schiff, E.R.4
Shiffman, M.L.5
Sulkowski, M.S.6
Wright, T.7
Younossi, Z.8
Goon, B.L.9
Tang, K.L.10
Bowers, P.J.11
-
47
-
-
0041822106
-
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
-
DOI 10.1053/jhep.2003.50364
-
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologie response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003;38:645-52. (Pubitemid 37052151)
-
(2003)
Hepatology
, vol.38
, Issue.3
, pp. 645-652
-
-
Davis, G.L.1
Wong, J.B.2
McHutchison, J.G.3
Manns, M.P.4
Harvey, J.5
Albrecht, J.6
-
48
-
-
33749360440
-
Effect of ribavirin in genotype 1 patients with hepatitis c responding to pegylated interferon alfa-2a plus ribavirin
-
DOI 10.1053/j.gastro.2006.07.022, PII S0016508506016659
-
Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006;131:1040-8. (Pubitemid 44515099)
-
(2006)
Gastroenterology
, vol.131
, Issue.4
, pp. 1040-1048
-
-
Bronowicki, J.1
Ouzan, D.2
Asselah, T.3
Desmorat, H.4
Zarski, J.5
Foucher, J.6
Bourliere, M.7
Renou, C.8
Tran, A.9
Melin, P.10
Hezode, C.11
Chevalier, M.12
Bouvier-Alias, M.13
Chevaliez, S.14
Montestruc, F.15
Lonjon-Domanec, I.16
Pawlotsky, J.17
-
49
-
-
33846246344
-
Impact of ribavirin dose reductions in hepatitis c virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment
-
DOI 10.1016/j.cgh.2006.10.008, PII S1542356506010469
-
Reddy KR, Shiffman ML, Morgan TR, Zeuzem S, Hadziyannis S, Hamzeh FM et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007;5:124-9. (Pubitemid 46096836)
-
(2007)
Clinical Gastroenterology and Hepatology
, vol.5
, Issue.1
, pp. 124-129
-
-
Reddy, K.R.1
Shiffman, M.L.2
Morgan, T.R.3
Zeuzem, S.4
Hadziyannis, S.5
Hamzeh, F.M.6
Wright, T.L.7
Fried, M.8
-
50
-
-
34249040959
-
The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1
-
Barcena R, Moreno A, del Campo S, Muriel A, Mateos ML, Garrido E et al. The magnitude of week 4 HCV RNA decay on pegylated interferon/ribavirin accurately predicts virological failure in patients with genotype 1. Antivir Ther 2007; 12:401 -6.
-
(2007)
Antivir Ther
, vol.12
, pp. 401-406
-
-
Barcena, R.1
Moreno, A.2
Del Campo, S.3
Muriel, A.4
Mateos, M.L.5
Garrido, E.6
-
51
-
-
23444460553
-
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
-
DOI 10.1016/j.jhep.2005.04.009, PII S016882780500320X
-
Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Gonçales FL Jr et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol 2005;43:425-33. (Pubitemid 41111423)
-
(2005)
Journal of Hepatology
, vol.43
, Issue.3
, pp. 425-433
-
-
Ferenci, P.1
Fried, M.W.2
Shiffman, M.L.3
Smith, C.I.4
Marinos, G.5
Goncales Jr., F.L.6
Haussinger, D.7
Diago, M.8
Carosi, G.9
Dhumeaux, D.10
Craxi, A.11
Chaneac, M.12
Reddy, K.R.13
-
52
-
-
54449089071
-
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: Randomized study of higher doses of peginterferon alpha-2a and ribavirin
-
Fried MW, Jensen DM, Rodriguez-Torres M, Nyberg LM, Di Bisceglie AM, Morgan TR et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology 2008;48:1033-43.
-
(2008)
Hepatology
, vol.48
, pp. 1033-1043
-
-
Fried, M.W.1
Jensen, D.M.2
Rodriguez-Torres, M.3
Nyberg, L.M.4
Di Bisceglie, A.M.5
Morgan, T.R.6
-
53
-
-
33646590308
-
Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy
-
DOI 10.1002/hep.21159
-
Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60. (Pubitemid 43724620)
-
(2006)
Hepatology
, vol.43
, Issue.5
, pp. 954-960
-
-
Jensen, D.M.1
Morgan, T.R.2
Marcellin, P.3
Pockros, P.J.4
Reddy, K.R.5
Hadziyannis, S.J.6
Ferenci, P.7
Ackrill, A.M.8
Willems, B.9
-
54
-
-
33644806944
-
Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C
-
DOI 10.1002/hep.21002
-
Martinez-Bauer E, Crespo J, Romero-Gómez M, Moreno-Otero R, Sola R, Tesei N et al. Development and validation of two models for early prediction of response to therapy in genotype 1 chronic hepatitis C. Hepatology 2006;43:72-80. (Pubitemid 43733593)
-
(2006)
Hepatology
, vol.43
, Issue.1
, pp. 72-80
-
-
Martinez-Bauer, E.1
Crespo, J.2
Romero-Gomez, M.3
Moreno-Otero, R.4
Sola, R.5
Tesei, N.6
Pons, F.7
Forns, X.8
Sanchez-Tapias, J.M.9
-
55
-
-
28844451934
-
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
-
DOI 10.1016/j.jhep.2005.10.003, PII S0168827805006677
-
Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103. (Pubitemid 41772522)
-
(2006)
Journal of Hepatology
, vol.44
, Issue.1
, pp. 97-103
-
-
Zeuzem, S.1
Buti, M.2
Ferenci, P.3
Sperl, J.4
Horsmans, Y.5
Cianciara, J.6
Ibranyi, E.7
Weiland, O.8
Noviello, S.9
Brass, C.10
Albrecht, J.11
-
56
-
-
79958816097
-
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection
-
Fried MW, Hadziyannis SJ, Shiffman ML, Messinger D, Zeuzem S. Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. J Hepatol 2011;55:69-75.
-
(2011)
J Hepatol
, vol.55
, pp. 69-75
-
-
Fried, M.W.1
Hadziyannis, S.J.2
Shiffman, M.L.3
Messinger, D.4
Zeuzem, S.5
-
57
-
-
77749341043
-
The German guidelines on the management of HCV infection
-
Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection
-
Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, Neumann U et al. [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010;48:289-351.
-
(2010)
Z Gastroenterol
, vol.48
, pp. 289-351
-
-
Sarrazin, C.1
Berg, T.2
Ross, R.S.3
Schirmacher, P.4
Wedemeyer, H.5
Neumann, U.6
-
58
-
-
0036788338
-
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C
-
McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:1061-9.
-
(2002)
Gastroenterology
, vol.123
, pp. 1061-1069
-
-
McHutchison, J.G.1
Manns, M.2
Patel, K.3
Poynard, T.4
Lindsay, K.L.5
Trepo, C.6
-
59
-
-
77957233758
-
Meta-analysis: Re-treatment of genotype i hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy
-
Singal AG, Waljee AK, Shiffman M, Bacon BR, Schoenfeld PS. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy. Aliment Pharmacol Ther 2010;32:969-83.
-
(2010)
Aliment Pharmacol Ther
, vol.32
, pp. 969-983
-
-
Singal, A.G.1
Waljee, A.K.2
Shiffman, M.3
Bacon, B.R.4
Schoenfeld, P.S.5
-
60
-
-
79960698392
-
Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment
-
Floreani A, Cazzagon N, Furlan P, Baldovin T, Egoue J, Antoniazzi S et al. Retreatment of patients with chronic hepatitis C relapsers to a previous antiviral treatment. Eur J Gastroenterol Hepatol 2011;23:711-5.
-
(2011)
Eur J Gastroenterol Hepatol
, vol.23
, pp. 711-715
-
-
Floreani, A.1
Cazzagon, N.2
Furlan, P.3
Baldovin, T.4
Egoue, J.5
Antoniazzi, S.6
-
61
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-17.
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
-
62
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
Jacobson, I.M., et al., Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011-,364:2405-16.
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
-
63
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med, 2011;364:1195-206.
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone Jr., J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
-
64
-
-
80052826527
-
Response-guided telaprevir combination treatment for hepatitis C virus infection
-
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-24.
-
(2011)
N Engl J Med
, vol.365
, pp. 1014-1024
-
-
Sherman, K.E.1
Flamm, S.L.2
Afdhal, N.H.3
Nelson, D.R.4
Sulkowski, M.S.5
Everson, G.T.6
-
65
-
-
79959381354
-
Telaprevir for retreatment of HCV infection
-
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
-
(2011)
N Engl J Med
, vol.364
, pp. 2417-2428
-
-
Zeuzem, S.1
Andreone, P.2
Pol, S.3
Lawitz, E.4
Diago, M.5
Roberts, S.6
-
66
-
-
79251554986
-
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C
-
e1; quiz e14
-
Marcellin P, Forns X, Goeser T, Ferenci P, Nevens F, Carosi G et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011;140:459-68 e1; quiz e14.
-
(2011)
Gastroenterology
, vol.140
, pp. 459-468
-
-
Marcellin, P.1
Forns, X.2
Goeser, T.3
Ferenci, P.4
Nevens, F.5
Carosi, G.6
-
67
-
-
0034720668
-
Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV)
-
Schvarcz R, Rudbeck G, Söderdahl G, Ståhle L. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 2000;69:2194-5. (Pubitemid 30395060)
-
(2000)
Transplantation
, vol.69
, Issue.10
, pp. 2194-2195
-
-
Schvarcz, R.1
Rudbeck, G.2
Soderdahl, G.3
Stahle, L.4
-
68
-
-
84862907480
-
Synthesis of stable isotope labeled analogs of the anti-hepatitis c virus nucleotide prodrugs psi-7977 and psi-352938
-
Chun BK, Du J, Zhang HR, Chang W, Ross BS, Jiang Y et al. Synthesis of Stable Isotope Labeled Analogs of the Anti-Hepatitis C Virus Nucleotide Prodrugs PSI-7977 and PSI-352938. Nucleosides Nucleotides Nucleic Acids 2011;30:886-96.
-
(2011)
Nucleosides Nucleotides Nucleic Acids
, vol.30
, pp. 886-896
-
-
Chun, B.K.1
Du, J.2
Zhang, H.R.3
Chang, W.4
Ross, B.S.5
Jiang, Y.6
|